---
title: Septic Shock Management Protocol
summary: Evidence-based approach to hemodynamic support in septic shock using the enhanced AutoFlow knowledge graph.
---

# Septic Shock Management Protocol

## Pathophysiology

Septic shock represents a complex pathophysiological state characterized by distributive shock with underlying circulatory and cellular metabolism abnormalities.

### Key Pathophysiological Mechanisms

**Vasodilation:**
- Nitric oxide-mediated smooth muscle relaxation
- Inflammatory mediator-induced endothelial dysfunction
- Loss of vascular autoregulation

**Myocardial Depression:**
- Cytokine-induced myocardial dysfunction
- Mitochondrial dysfunction
- Calcium handling abnormalities

**Microcirculatory Dysfunction:**
- Heterogeneous tissue perfusion
- Arteriovenous shunting
- Capillary leak syndrome

## Initial Resuscitation Bundle (Hour 1)

### Fluid Resuscitation
- **Crystalloid:** 30 mL/kg balanced crystalloid within first 3 hours
- **Assessment:** Serial lactate, urine output, capillary refill
- **Targets:** MAP ≥65 mmHg, CVP 8-12 mmHg

### Source Control
- **Blood cultures:** Obtain before antibiotics when feasible
- **Imaging:** Identify and drain infectious sources
- **Antibiotics:** Broad-spectrum within 1 hour

### Hemodynamic Support
- **Vasopressors:** Initiate if hypotension persists after fluid resuscitation
- **Monitoring:** Arterial line, central venous access
- **Targets:** MAP ≥65 mmHg, ScvO₂ ≥70%

## Vasopressor Selection Algorithm

### First-Line: Norepinephrine
**Indications:**
- Septic shock with adequate cardiac output
- Distributive shock requiring vasoconstriction
- MAP <65 mmHg despite fluid resuscitation

**Dosing Protocol:**
1. Start: 0.01 mcg/kg/min (5-10 mcg/min)
2. Titrate: Increase by 0.01-0.02 mcg/kg/min every 5-10 minutes
3. Target: MAP ≥65 mmHg
4. Maximum: 3-5 mcg/kg/min (consider second agent)

### Second-Line: Vasopressin
**Indications:**
- Catecholamine-resistant shock
- Norepinephrine dose >0.5 mcg/kg/min
- Adjunctive therapy to reduce norepinephrine requirements

**Dosing:**
- Fixed dose: 0.01-0.04 units/min
- Not titrated based on blood pressure
- Duration: Consider weaning after 24-48 hours

### Third-Line: Epinephrine
**Indications:**
- Refractory shock despite norepinephrine + vasopressin
- Concurrent cardiac dysfunction
- Anaphylactic component suspected

**Monitoring:**
- Increased risk of tachyarrhythmias
- Monitor cardiac enzymes
- Watch for peripheral ischemia

## Monitoring and Targets

### Hemodynamic Monitoring
- **MAP:** ≥65 mmHg (individualize based on baseline)
- **Cardiac Index:** ≥2.5 L/min/m² (if measured)
- **SVR:** 800-1200 dyne·s/cm⁻⁵
- **PCWP:** 12-18 mmHg (if Swan-Ganz catheter)

### Tissue Perfusion Markers
- **Lactate:** <2 mmol/L (or clearance ≥20% in 6 hours)
- **ScvO₂:** ≥70% (central venous oxygen saturation)
- **Urine output:** ≥0.5 mL/kg/hr
- **Capillary refill:** <3 seconds

### Laboratory Monitoring
- **Complete metabolic panel:** Every 6-12 hours
- **Liver function:** AST/ALT (with high-dose vasopressors)
- **Arterial blood gas:** Monitor acid-base status
- **Coagulation studies:** PT/INR, fibrinogen, D-dimer

## Advanced Hemodynamic Support

### Inotropic Support
**Dobutamine:**
- Indications: Myocardial dysfunction with adequate preload
- Dosing: 2.5-20 mcg/kg/min
- Monitoring: Risk of hypotension, arrhythmias

**Milrinone:**
- Indications: Cardiogenic shock with high SVR
- Dosing: Load 50 mcg/kg, then 0.25-0.75 mcg/kg/min
- Caution: Vasodilation may worsen hypotension

### Mechanical Support
**Intraaortic Balloon Pump (IABP):**
- Cardiogenic shock with preserved peripheral circulation
- Augments diastolic pressure and reduces afterload

**Extracorporeal Membrane Oxygenation (ECMO):**
- Refractory cardiogenic shock
- Bridge to recovery or transplantation

## Adjunctive Therapies

### Corticosteroids
**Hydrocortisone:**
- Refractory shock requiring >0.25 mcg/kg/min norepinephrine
- Dose: 200-300 mg/day (divided or continuous)
- Duration: 5-7 days with gradual taper

### Specialized Vasopressors
**Angiotensin II (Giapreza):**
- Catecholamine-resistant distributive shock
- Dose: 5-40 ng/kg/min
- Monitor: Thrombotic complications

**Methylene Blue:**
- Refractory vasoplegia
- Dose: 1-2 mg/kg bolus, then 0.25-2 mg/kg/hr
- Monitor: Serotonin syndrome risk with SSRIs

## Weaning Strategy

### Vasopressor Weaning
1. **Stabilization:** Maintain targets for 12-24 hours
2. **Sequential weaning:** Reduce most recently added agent first
3. **Dose reduction:** 25-50% decrements every 30-60 minutes
4. **Monitoring:** Continuous MAP, lactate clearance

### Endpoint Assessment
- **Clinical improvement:** Mental status, urine output
- **Hemodynamic stability:** Sustained MAP without escalation
- **Metabolic clearance:** Lactate normalization
- **Organ function:** Improvement in SOFA score

## Complications and Management

### Peripheral Ischemia
- **Recognition:** Cool extremities, mottled skin, weak pulses
- **Management:** Dose reduction, alternative agents, surgical consultation
- **Prevention:** Lowest effective dose, central administration

### Cardiac Arrhythmias
- **Risk factors:** High-dose catecholamines, electrolyte imbalances
- **Management:** Correct electrolytes, consider alternative agents
- **Monitoring:** Continuous telemetry, 12-lead ECG changes

### Extravasation Injury
- **Prevention:** Central venous administration preferred
- **Treatment:** Phentolamine 5-10 mg in 10-15 mL saline infiltration
- **Monitoring:** Regular assessment of infusion sites
